Transforming cancer treatment and advancing new therapies through empowered science

Corporate Profile

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.

The company’s lead product, ADCETRIS® (brentuximab vedotin) is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited is commercially available for two indications in more than 40 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage ADC programs designed to address the unmet medical needs of people with cancer, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, ASG-22ME and ASG-15ME. Seattle Genetics’ ADC technology is employed by a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. Across both internal and collaborator programs, there are more than 20 ADCs in clinical development using our proprietary approach to empowering antibodies.

Download Documentation  Corporate Fact Sheet
Download Documentation  2013 Annual Report
Download Documentation  2014 Proxy Statement
Investor Contact
Peggy Pinkston
Senior Director, Corporate Communications
PHONE: (425) 527-4160
FAX: (425) 527-4001
EMAIL: ppinkston@seagen.com

Media Contact
Tricia Larson
Director, Public Relations
PHONE: 425-527-4180
EMAIL: tlarson@seagen.com
Stock Quote
SGEN (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$44.01
Change (%) Stock is Up 0.44 (1.01%)
Volume522,970
Data as of 08/29/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >
DateTitle 
08/12/14Seattle Genetics Initiates Phase 1 Clinical Trial of Antibody-Drug Conjugate SGN-CD70A for Non-Hodgkin Lymphoma and Renal Cell Carcinoma
-Sixth Proprietary ADC in Clinical Development for the Treatment of Cancer- -Second Proprietary ADC Program Utilizing Newest ADC Technology to Advance into Clinical Trials- BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 12, 2014-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced the initiation of a phase 1 clinical trial evaluating SGN-CD70A for CD70-positive relapsed or refractory non-Hodgkin lymphoma (NHL) and metastatic renal cell... 
Printer Friendly Version
07/31/14Seattle Genetics Reports Second Quarter 2014 Financial Results
-Total Second Quarter Revenues of $68.3 Million, Including $44.8 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Product Sales- -ADCETRIS 2014 Net Sales Guidance Increased to a Range of $160 million to $170 million- -ADCETRIS Phase 3 AETHERA Clinical Trial Top-Line Data to be Reported by October 2014- -Conference Call Today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--Jul. 31, 2014-- Se... 
Printer Friendly Version
07/09/14Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2014 Financial Results on July 31, 2014
BOTHELL, Wash.--(BUSINESS WIRE)--Jul. 9, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its second quarter 2014 financial results on Thursday, July 31, 2014, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access o... 
Printer Friendly Version
06/01/14Seattle Genetics Presents Data from Phase 1 Clinical Trial of Antibody-Drug Conjugate (ADC) SGN-CD19A in Non-Hodgkin Lymphoma at ASCO Annual Meeting
CHICAGO--(BUSINESS WIRE)--Jun. 1, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) today will present interim phase 1 clinical data from SGN-CD19A, an antibody-drug conjugate (ADC) in development for the treatment of B-cell malignancies, at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting being held May 30 to June 3, 2014 in Chicago, IL. SGN-CD19A is an ADC targeting CD19, a protein expressed on B-cell malignancies. “... 
Printer Friendly Version
05/31/14Seattle Genetics Highlights Data from Multiple Collaborator Antibody-Drug Conjugate (ADC) Programs at ASCO Annual Meeting
-AbbVie Presents First Phase 1 Data Evaluating Novel ADC Candidate ABT-414 in Glioblastoma- -Genentech Presents Preliminary Phase 2 Results Evaluating Two ADC Candidates, Polatuzumab Vedotin and Pinatuzumab Vedotin, in Relapsed/Refractory Non-Hodgkin Lymphoma- CHICAGO--(BUSINESS WIRE)--May 31, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from several collaborator antibody-drug conjugate (ADC) programs present... 
Printer Friendly Version
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.